NDAINTRAVENOUSSOLUTION
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
POSFREA (palonosetron) by Viatris (2) is 5-ht 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Approved for chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POSFREA (palonosetron) is a highly selective 5-HT3 receptor antagonist approved for preventing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). It works by blocking serotonin signaling at vagal nerve terminals and the chemoreceptor trigger zone, preventing the cascade of neuronal events that trigger emesis. The drug is administered intravenously as a solution.
Peak
Product is at peak commercial maturity under Viatris with moderate competitive pressure (30/100), suggesting stable team size but limited growth trajectory.
Mechanism of Action
5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located…
Indications (2)
Worked on POSFREA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.